Intravesical Therapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence-Reference-Cited by-同舟云学术

Intravesical Therapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence

Published:2021-03 Issue: Volume: Page:
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Laukhtina Ekaterina^ORCID,Abufaraj Mohammad,Al-Ani Abdallah,Ali Mustafa Rami,Mori Keiichiro,Moschini Marco,Quhal Fahad,Sari Motlagh Reza,Pradere Benjamin,Schuettfort Victor M.,Mostafaei Hadi,Katayama Satoshi,Grossmann Nico C.,Fajkovic Harun,Soria Francesco,Enikeev Dmitry,Shariat Shahrokh F.

Publisher

Elsevier BV

Subject

Urology

Reference41 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

3. Guideline of guidelines: non-muscle-invasive bladder cancer;Woldu;BJU Int,2017

4. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS);Witjes;BJU Int,2013

5. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin;Cambier;Eur Urol,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitomycin C vs. Bacillus Calmette–Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients—A comparative analysis from a single center;Urologic Oncology: Seminars and Original Investigations;2024-07

2. Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review;Journal of Clinical Medicine;2024-06-27

3. Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer;European Urology Oncology;2024-06

4. The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis;European Urology Oncology;2024-06

5. Editorial: Urological cancer awareness month – 2022;Frontiers in Urology;2024-05-20